EFC15935

Research code: EFC15935
Research name: Randomised, multicentre, double-blind phase 3 research evaluating combination treatment: SAR439859 and palbociclib compared with letrozole and palbociclib in patients with ER(+) and HER2(-) breast cancer not previously treated for advanced disease.
Indication: breast cancer
Principal researcher: Ewa Chmielowska, MD, PhD